1.06
+0.03(+2.91%)
Currency In USD
| Previous Close | 1.03 |
| Open | 1 |
| Day High | 1.14 |
| Day Low | 1 |
| 52-Week High | 5 |
| 52-Week Low | 0.96 |
| Volume | 88,334 |
| Average Volume | 83,714 |
| Market Cap | 6.47M |
| PE | -0.5 |
| EPS | -2.12 |
| Moving Average 50 Days | 1.36 |
| Moving Average 200 Days | 1.71 |
| Change | 0.03 |
If you invested $1000 in Aprea Therapeutics, Inc. (APRE) since IPO date, it would be worth $2.59 as of December 05, 2025 at a share price of $1.06. Whereas If you bought $1000 worth of Aprea Therapeutics, Inc. (APRE) shares 5 years ago, it would be worth $1.73 as of December 05, 2025 at a share price of $1.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
GlobeNewswire Inc.
Oct 24, 2025 12:30 PM GMT
3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in patients with tumors harboring mutations relevant to
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
GlobeNewswire Inc.
Oct 15, 2025 12:00 PM GMT
ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation studyFurther ATRN-119 monotherapy enrollment paused with strategic focus on high-value combinationCompany is prioritizing its lead program, WEE1 kin
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
DOYLESTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities wh